Pascal Soriot

Pascal Soriot
Virginia Office of the Governor · CC BY 4.0 · source
Name	Pascal Soriot
Birth date	1959
Birth place	Sèvremoine, Maine-et-Loire, France
Occupation	Business executive
Known for	Chief Executive Officer of AstraZeneca

Pascal Soriot is a French-born business executive known for his tenure as Chief Executive Officer of AstraZeneca, a multinational AstraZeneca pharmaceutical company. He has led major strategic shifts, global research collaborations, and commercial expansions across markets including United States, United Kingdom, China, India, and European Union member states. Soriot's career spans roles at multinational corporations such as Rhone-Poulenc, Hoffmann-La Roche, Genentech, and MediChem before joining AstraZeneca.

Early life and education

Born in Sèvremoine, Maine-et-Loire, France, Soriot attended secondary schooling in the Pays de la Loire region before pursuing higher education at the École nationale vétérinaire d'Alfort, where he trained as a veterinarian. He later obtained management training that connected him to corporate leadership pathways prominent in France and United Kingdom business networks, aligning him with alumni and professional circles including executives from TotalEnergies, Sanofi, Danone, and L'Oréal.

Career

Soriot began his career as a veterinarian before transitioning to the pharmaceutical industry, holding positions at Rhone-Poulenc and Hoffmann-La Roche where he worked alongside global teams involved in drug development and commercialization. He joined Genentech and later joined MediChem, contributing to projects intersecting with research at institutions such as Massachusetts Institute of Technology, Harvard University, Johns Hopkins University, University of Cambridge, and University of Oxford. His roles involved partnerships with biotechnology firms including Amgen, Biogen, Gilead Sciences, Regeneron Pharmaceuticals, and Moderna.

Prior to AstraZeneca, Soriot served in senior leadership at Roche subsidiaries and participated in strategic alliances with organizations such as GlaxoSmithKline, Pfizer, Novartis, Merck & Co., Bristol-Myers Squibb, and Eli Lilly and Company. He was involved in merger and acquisition discussions, licensing agreements, and collaborations with academic research centers like Imperial College London and Karolinska Institutet that influenced translational medicine pipelines.

Leadership at AstraZeneca

Soriot became CEO of AstraZeneca during a period of transformation, steering the company through portfolio restructuring, pipeline prioritization, and global expansion into markets with regulatory landscapes shaped by entities such as the European Medicines Agency and the U.S. Food and Drug Administration. Under his leadership, AstraZeneca advanced oncology programs collaborating with specialists at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Research Center, while also accelerating vaccine and antiviral efforts in partnership with universities including University of Oxford and biotech firms like Moderna and CureVac.

Soriot's tenure encompassed high-profile responses to public health crises, coordination with governments including United Kingdom Government, United States Department of Health and Human Services, World Health Organization, and procurement negotiations across the European Union and G7. He oversaw regulatory submissions and approvals across jurisdictions, interactions with agencies such as Health Canada, Therapeutic Goods Administration (Australia), and Japan Pharmaceuticals and Medical Devices Agency, and collaborations with contract manufacturers and suppliers including Thermo Fisher Scientific and Novasep.

Strategic initiatives under Soriot included investments in biopharmaceutical research, digital health collaborations with technology companies like Microsoft, Google, and IBM Watson Health, and alliances with contract research organizations such as IQVIA and PPD. AstraZeneca's business development deals involved counterparties like Vertex Pharmaceuticals, Astellas Pharma, Takeda Pharmaceutical Company, and CSL Limited.

Compensation and board memberships

As CEO, Soriot's compensation packages referenced corporate governance standards influenced by bodies such as the Financial Reporting Council (United Kingdom) and shareholder groups including Institutional Shareholder Services and Glass Lewis. His remuneration and incentive structures were subject to approvals by AstraZeneca's board and major institutional investors including BlackRock, Vanguard Group, Fidelity Investments, State Street Corporation, and activist stakeholders like Elliott Management Corporation.

Soriot has held or been associated with board-level roles and advisory positions interacting with corporations, academic institutions, and non-profit organizations, engaging with peers from Johnson & Johnson, Siemens, Bayer, ABB, and research foundations such as the Bill & Melinda Gates Foundation.

Honours and recognition

Soriot received honors and public recognition from national and industry bodies, including awards and listings by publications such as the Financial Times, Bloomberg, Forbes, The Economist, and The Sunday Times. He earned distinctions linked to contributions to life sciences and industry leadership, drawing acknowledgement from organizations like the Royal Society, Academy of Medical Sciences (United Kingdom), and national honors systems in France and the United Kingdom for services to business and healthcare collaboration.

Category:French chief executives Category:1959 births Category:Living people